Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On
NSCLC
Viscum album L
advanced
lung cancer
nonmetastasized
overall survival
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
19
8
2021
Statut:
ppublish
Résumé
Recent data suggest a beneficial effect of add-on treatment with The multicenter real-world data study was conducted using data from the Network Oncology Clinical Registry. The primary end point was OS. OS and impact on hazard in both treatment groups were compared. A total of 275 patients with stages I to IIIA NSCLC were enrolled (mean age = 67.6 years, 57.2% male patients). No significant difference of OS was observed between both groups. Even though not significant, for a subgroup of unresected patients with stage I NSCLC, adenocarcinoma or squamous cell carcinoma, a medium effect size OS improvement was observed for S+VA compared to S. Our findings support the importance of surgery as the most effective intervention in nonmetastasized NSCLC patients. Add-on VA therapy shows here no additional effect in resected patients. However, a small subgroup analysis suggests a possible role of add-on VA for nonresected subgroups. Our results complement existing knowledge on the clinical impact of add-on VA therapy in NSCLC patients and may serve as hypothesis-generating data for further examinations in this cohort. Further research could be directed towards the role of combined therapy for nonresected early-stage NSCLC.
Sections du résumé
BACKGROUND
Recent data suggest a beneficial effect of add-on treatment with
METHODS
The multicenter real-world data study was conducted using data from the Network Oncology Clinical Registry. The primary end point was OS. OS and impact on hazard in both treatment groups were compared.
RESULTS
A total of 275 patients with stages I to IIIA NSCLC were enrolled (mean age = 67.6 years, 57.2% male patients). No significant difference of OS was observed between both groups. Even though not significant, for a subgroup of unresected patients with stage I NSCLC, adenocarcinoma or squamous cell carcinoma, a medium effect size OS improvement was observed for S+VA compared to S.
CONCLUSIONS
Our findings support the importance of surgery as the most effective intervention in nonmetastasized NSCLC patients. Add-on VA therapy shows here no additional effect in resected patients. However, a small subgroup analysis suggests a possible role of add-on VA for nonresected subgroups. Our results complement existing knowledge on the clinical impact of add-on VA therapy in NSCLC patients and may serve as hypothesis-generating data for further examinations in this cohort. Further research could be directed towards the role of combined therapy for nonresected early-stage NSCLC.
Identifiants
pubmed: 32856476
doi: 10.1177/1534735420940384
pmc: PMC7457695
doi:
Substances chimiques
Plant Extracts
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735420940384Références
Arzneimittelforschung. 2004;54(8):456-66
pubmed: 15460213
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Altern Ther Health Med. 2001 May-Jun;7(3):57-66, 68-72, 74-6 passim
pubmed: 11347286
BMC Cancer. 2016 Aug 02;16:579
pubmed: 27485618
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003297
pubmed: 18425885
Eur J Cancer. 2013 Mar;49(5):1058-64
pubmed: 23218588
Control Clin Trials. 2003 Dec;24(6):682-701
pubmed: 14662274
J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58
pubmed: 25749602
J Altern Complement Med. 2018 Sep/Oct;24(9-10):862-871
pubmed: 30247955
Eur J Med Res. 2007 Mar 26;12(3):103-19
pubmed: 17507307
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Forsch Komplementmed. 2013;20(5):353-60
pubmed: 24200825
Complement Ther Med. 2018 Oct;40:151-157
pubmed: 30219441
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Explore (NY). 2012 Sep-Oct;8(5):277-81
pubmed: 22938746
BMC Cancer. 2009 Dec 18;9:451
pubmed: 20021637
Integr Cancer Ther. 2014 Jul;13(4):332-40
pubmed: 24363283
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
PLoS One. 2018 Aug 27;13(8):e0203058
pubmed: 30148853
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 29059439
Evid Based Complement Alternat Med. 2014;2014:430518
pubmed: 24701238
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
Evid Based Complement Alternat Med. 2012;2012:219402
pubmed: 21747894
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur J Med Res. 2003 Mar 27;8(3):109-19
pubmed: 12730032
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Eur J Cancer. 2013 Dec;49(18):3788-97
pubmed: 23890767
J Clin Oncol. 2018 Jun 10;36(17):1675-1684
pubmed: 29570421
GMS Health Technol Assess. 2006 Sep 19;2:Doc18
pubmed: 21289969
Complement Med Res. 2020;27(4):260-271
pubmed: 31927541